1. 高安右人．奇異ナル網膜中心血管ノ変化ノ一例．日本眼 科学会雑誌．1908; 12: 554-555.
2. Shimizu K, Sano K. Pulseless disease. J Neuropathol Clin Neurol. 1951; 1: 37-47.
3. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 1994; 37 (2): 187-192.
4. Hutchinson J. Diseases of the arteries. Arch. Surg. 1890; 1:
323-333.
5. Bruce W. Senile rheumatic gout. Br Med J. 1888; ii:
811-813.
6. Buerger L. Thrombo-angitis obliterance: A study of the vascular lesions leading to presenile spontaneous gangrene.
Am J Med Sci. 1908; 136: 567-580.
7. Buerger L. The vein in Thromboangitis obliterans. JAMA.
1909; 52: 1319.
8. Kussmaul A, Maier R. Über eine bisher nicht beschribene eigenthümliche Arterienerkrankung (Periarteritis nodosa), die mit Morbus Brightii und rapid fortschreitender allgemeineer Muskellähmung einhergeht. Dtsh Arch Klin Med. 1866; 1:
484-517.
9. 川崎富作．指趾の特異的落屑を伴う小児の急性熱性皮膚 粘膜淋巴腺症候群，自験例50例の臨床的観察．アレルギー．
1967; 16: 178-222.
10. Klemperer P, Pollack AD, Baehr G. Diffuse collagen disease. JAMA. 1942; 119: 331-332.
11. Zeek PM. Periarteritis nodosa; a critical review. Am J Clin Pathol. 1952; 22 (8): 777-790.
12. Bevans M, Nadell J, Demartini F, et al. The systemic lesions of malignant rheumatoid arthritis. Am J Med. Feb 1954; 16 (2): 197-211.
13. Wohlwill F. Über die nur mikroscopisch erkennbare Form der Periarteritis Nodosa. Virch. Arch. Pathol. Anat. Physiolg.
Klin. Med. 1923; 246: 377-413.
14. Arkin A. A clinical and pathological study of periarteritis nodosa. A report of 5 cases, one histologically healed. Am J Pathol. 1936; 6: 401-427.
15. Wegener F. Über eine eigenartige rhinogene Guranulomatose mit besonderer beteilgung des Arteriensystems under der Nieren. Beitr Pathol Anat. 1939; 102: 36-68.
16. Churg J, Strauss L. Allergic granulomatosis, allergic angiitis, and periarteritis nodosa. Am J Pathol. 1951; 27 (2):
277-301.
17. Davies DJ, Moran JE, Niall JF, et al. Segmental necrotising glomerulonephritis with antineutrophil antibody: possible arbovirus aetiology? Br Med J (Clin Res Ed). 1982; 285 (6342): 606.
18. Jennette JC, Falk RJ. Small-vessel vasculitis. N Engl J Med. 1997; 337 (21): 1512-1523.
19. Nawata H, Soen S, Takayanagi R, et al. Guidelines on the management and treatment of glucocorticoid-induced
osteoporosis of the Japanese Society for Bone and Mineral Research (2004). J Bone Miner Metab. 2005; 23 (2): 105-109.
20. 折茂肇．骨粗鬆症の予防治療ガイドライン2006 年版．
ライフサイエンス社．2006.
21. 橋本博史．免疫疾患の合併症とその治療法に関する研究
「診療ガイドライン」．厚生労働科学免疫アレルギー疾患予 防・治療研究事業，免疫疾患の合併症とその治療法に関す る研究班編．2005.
22. Nesher G, Berkun Y, Mates M, et al. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum. 2004; 50 (4): 1332-1337.
23. 磯部光章．高安病update. Cardiovasc Med-Surg. 2006; 8:
169-174.
24. Numano F. Takayasu arteritis-five doctors in the history of Takayasu arteritis. Int J Cardiol. 1966; 54 (Sup 1): 1-10.
25. Numano F, Okawara M, Inomata H, et al. Takayasu’s arteritis. Lancet. 2000; 356 (9234): 1023-1025.
26. 沼野藤夫．高安動脈炎（大動脈炎症候群，脈なし病）．
日本内科学会雑誌．2002; 91: 76-80.
27. 矢数道明．脈なし病記載の漢方医書とその著者山本鹿洲 翁．日本医事新報．1966; 57 (27-30): 27.
28. Savory W. Royal Medical and Surgical Society on a case of young woman in whom the main arteries of both upper extremities and of the left side of the neck were throughout completely obliterated. Lancet. 1856; 5: 373.
29. 新見保三．高安病の一症例．総合眼科．1942; 36: 1402.
30. Caccamise WC, Whitman JF. Pulse-less disease; a preliminary case report. Am Heart J. 1952; 44 (4): 628-633.
31. Ueda H. Immunological studies of aortitis syndrome. Jpn Heart J. 1967; 8: 4-18.
32. Ito I, Saito Y, Nonaka Y. Immunological aspects of aortitis syndrome. Jpn Circ J. 1975; 39 (4): 459-462.
33. Numano F, Kobayashi Y. Takayasu arteritis and Buerger Disease IV. Int J Cardiol. 2000; XX (Sup 1): 1-192.
34. 小林靖，沼野藤夫，中島伸之．大型血管炎の臨床に関す る小委員会報告 高安動脈炎（大動脈炎症候群）．厚生省 特定疾患免疫疾患調査研究班難治性血管炎分科会平成 年度報告書．1999: 171-184.
35. Bauer S, Groh V, Wu J, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA.
Science. 1999; 285 (5428): 727-729.
36. Seko Y, Minota S, Kawasaki A, et al. Perforin-secreting killer cell infiltration and expression of a 65-kD heat-shock protein in aortic tissue of patients with Takayasu’s arteritis. J Clin Invest. 1994; 93 (2): 750-758.
37. Seko Y, Sato O, Takagi A, et al. Restricted usage of T-cell receptor Valpha-Vbeta genes in infiltrating cells in aortic tissue of patients with Takayasu’s arteritis. Circulation. 1996;
93 (10): 1788-1790.
38. Seko Y, Takahashi N, Tada Y, et al. Restricted usage of T-cell receptor Vgamma-Vdelta genes and expression of
costimulatory molecules in Takayasu’s arteritis. Int J Cardiol.
2000; 75 Suppl 1: S77-83; discussion S85-77.
39. Seko Y, Sato O, Takagi A, et al. Perforin-secreting killer cell infiltration in the aortic tissue of patients with atherosclerotic aortic aneurysm. Jpn Circ J. 1997; 61 (12):
965-970.
40. Seko Y, Sugishita K, Sato O, et al. Expression of costimulatory molecules (4-1BBL and Fas) and major histocompatibility class I chain-related A (MICA) in aortic tissue with Takayasu’s arteritis. J Vasc Res. 2004; 41 (1):
84-90.
41. Kimura A, Kitamura H, Date Y, et al. Comprehensive analysis of HLA genes in Takayasu arteritis in Japan. Int J Cardiol. 1996; 54 Suppl: S61-69.
42. Kimura A, Kobayashi Y, Takahashi M, et al. MICA gene polymorphism in Takayasu’s arteritis and Buerger’s disease.
Int J Cardiol. 1998; 66 Suppl 1: S107-113; discussion S115.
43. Seyahi E, Ugurlu S, Cumali R, et al. Atherosclerosis in Takayasu arteritis. Ann Rheum Dis. 2006; 65 (9): 1202-1207.
44. 由谷親夫．血管炎症候群の病理．病理と臨床．2003; 21:
1007-1013.
45. 由谷親夫．炎症性動脈疾患．心臓血管病理アトラス，文 光堂．2002: 253-267.
46. 由谷親夫．高安動脈炎．血管炎アトラス，平成 年厚 生労働省難治性疾患克服研究事業・難治性血管炎に関する 調査研究班．2005: 5-8.
47. 小林靖，沼野藤夫．高安動脈炎．血管炎，朝倉書店．
2001: 192-198.
48. 小林靖．血管疾患と炎症-Up-to-Date，高安動脈炎（大 動脈炎症候群）．Angiology Frontier. 2004; 3: 31-36.
49. 小林靖．高安動脈炎．．難治性血管炎の診療マニュアル．
厚生科学研究特定疾患対策研究事業，難治性血管炎に関す る調査研究班．2002: 1-9.
50. Arnaud L, Kahn JE, Girszyn N, et al. Takayasu’s arteritis:
An update on physiopathology. Eur J Intern Med. 2006; 17 (4): 241-246.
51. Ito I. Medical treatment of Takayasu arteritis. Heart Vessels Suppl. 1992; 7: 133-137.
52. Hall S, Barr W, Lie JT, et al. Takayasu arteritis. A study of 32 North American patients. Medicine (Baltimore). 1985; 64 (2): 89-99.
53. Kerr GS, Hallahan CW, Giordano J, et al. Takayasu arteritis. Ann Intern Med. 1994; 120 (11): 919-929.
54. Shelhamer JH, Volkman DJ, Parrillo JE, et al. Takayasu’s arteritis and its therapy. Ann Intern Med. 1985; 103 (1):
121-126.
55. Ureten K, Ozturk MA, Onat AM, et al. Takayasu’s arteritis:
results of a university hospital of 45 patients in Turkey. Int J Cardiol. 2004; 96 (2): 259-264.
56. Maksimowicz KM, Clark TM, Hoffman GS. Limitations of thrapy and a guarded prognosis in an american cohort of Takayasu arteritis patients. Arthritis Rheum. 2007; 56 (3):
1000-1009.
57. Moriwaki R, Numano F. Takayasu arteritis: follow-up
studies for 20 years. Heart Vessels Suppl. 1992; 7: 138-145.
58. Kobayashi Y, Numano F. Takayasu arteritis. Intern Med.
2002; 41 (1): 44-46.
59. Nakamura T, Hayashi S, Fukuoka M, et al. Pulmonary infarction as the initial manifestation of Takayasu’s arteritis.
Intern Med. 2006; 45 (11): 725-728.
60. Shlomai A, Hershko AY, Gabbay E, et al. Clinical and radiographic features mimicking pulmonary embolism as the first manifestation of Takayasu’s arteritis. Clin Rheumatol.
2004; 23 (5): 470-472.
61. Numano F, Maruyama Y, Koyama T, et al. Antiaggregative aspirin dosage at the affected vessel wall. Angiology. 1986;
37 (10): 695-701.
62. Soto ME, Espinola-Zavaleta N, Ramirez-Quito O, et al.
Echocardiographic follow-up of patients with Takayasu’s arteritis: five-year survival. Echocardiography. 2006; 23 (5):
353-360.
63. Haubitz M, Schellong S, Gobel U, et al. Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study. Arthritis Rheum. 1998; 41 (10): 1835-1844.
64. Cohen P, Pagnoux C, Mahr A, et al. Churg-Strauss syndrome with poor-prognosis factors: A prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. Arthritis Rheum. 2007; 57 (4): 686-693.
65. Rodriguez-Hurtado FJ, Sabio JM, Lucena J, et al. Ocular i n v o l v e m e n t i n Ta k a y a s u ’ s a r t e r i t i s : r e s p o n s e t o cyclophosphamide therapy. Eur J Med Res. 2002; 7 (3):
128-130.
66. Hoffman GS, Leavitt RY, Kerr GS, et al. Treatment of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrexate. Arthritis Rheum. 1994; 37 (4): 578-582.
67. Valsakumar AK, Valappil UC, Jorapur V, et al. Role of immunosuppressive therapy on clinical, immunological, and angiographic outcome in active Takayasu’s arteritis. J Rheumatol. 2003; 30 (8): 1793-1798.
68. Wada K, Takada M, Ueda T, et al. Pharmacokinetic study and limited sampling strategy of cyclosporine in Japanese heart transplant recipients. Circ J. 2006; 70 (10): 1307-1311.
69. Fearfield LA, Ross JR, Farrell AM, et al. Pyoderma gangrenosum associated with Takayasu’s arteritis responding to cyclosporin. Br J Dermatol. Aug 1999; 141 (2): 339-343.
70. Ujiie H, Sawamura D, Yokota K, et al. Pyoderma gangrenosum associated with Takayasu’s arteritis. Clin Exp Dermatol. 2004; 29 (4): 357-359.
71. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000; 47 (2-3): 85-118.
72. Shinjo SK, Pereira RM, Tizziani VA, et al. Mycophenolate mofetil reduces disease activity and steroid dosage in Takayasu arteritis. Clin Rheumatol. 2007; 26 (11): 1871-1875.
73. Tripathy NK, Chauhan SK, Nityanand S. Cytokine mRNA repertoire of peripheral blood mononuclear cells in Takayasu’
s arteritis. Clin Exp Immunol. 2004; 138 (2): 369-374.
74. Hoffman GS, Merkel PA, Brasington RD, et al. Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum. 2004; 50 (7): 2296-2304.
75. Isenberg DA. B cell targeted therapies in autoimmune diseases. J Rheumatol Suppl. 2006; 77: 24-28.
76. Voltarelli JC, Oliveira MC, Stracieri AB, et al.
Haematopoietic stem cell transplantation for refractory Takayasu’s arteritis. Rheumatology (Oxford). 2004; 43 (10):
1308-1309.
77. Weaver FA, Yellin AE, Campen DH, et al. Surgical procedures in the management of Takayasu’s arteritis. J Vasc Surg. 1990; 12 (4): 429-437; discussion 438-429.
78. Takagi A, Tada Y, Sato O, et al. Surgical treatment for Takayasu’s arteritis. A long-term follow-up study. J Cardiovasc Surg (Torino). 1989; 30 (4): 553-558.
79. Kimoto S. The history and present status of aortic surgery in Japan, particularly for aortitis syndrome. J Cardiovasc Surg (Torino). 1979; 20 (2): 107-126.
80. Ishikawa K, Maetani S. Long-term outcome for 120 Japanese patients with Takayasu’s disease. Clinical and statistical analyses of related prognostic factors. Circulation.
1994; 90 (4): 1855-1860.
81. 榎本栄，宮本忠臣，島田一郎．大動脈炎症候群に合併し た大動脈閉鎖不全（AR）に対する外科治療の検討 Bentall 手 術 の 適 応 拡 大 に 関 し て．日 胸 外 会 誌．1992; 40 (4):
500-505.
82. Ando M, Kosakai Y, Okita Y, et al. Surgical treatment for aortic regurgitation caused by Takayasu’s arteritis. J Card Surg. 1998; 13 (3): 202-207.
83. Ando M, Okita Y, Sasako Y, et al. Evaluation of the results surgical treatment for dilative lesion associated with Takayasu’s arteritis. J Angiology. 2000; 9 (3): 1061-1711.
84. Isomura T, Hisatomi K, Yanagi I, et al. The surgical treatment of aortic regurgitation secondary to aortitis. Ann Thorac Surg. 1988; 45 (2): 181-185.
85. Suzuki A, Amano J, Tanaka H, et al. Surgical consideration of aortitis involving the aortic root. Circulation. 1989; 80 (3 Pt 1): I222-232.
86. Young JA, Sengupta A, Khaja FU. Coronary arterial stenosis, angina pectoris and atypical coarctation of the aorta due to nonspecific arteritis. Treatment with aortocoronary bypass graft. Am J Cardiol. 1973; 32 (3): 356-360.
87. Cipriano PR, Silverman JF, Perlroth MG, et al. Coronary arterial narrowing in Takayasu’s aortitis. Am J Cardiol. 1977;
39 (5): 744-750.
88. Lupi-Herrera E, Sanchez-Torres G, Marcushamer J, et al.
Takayasu’s arteritis. Clinical study of 107 cases. Am Heart J.
1977; 93 (1): 94-103.
89. Makino N, Orita Y, Takeshita A, et al. Coronary arterial involvement in Takayasu’s disease. Jpn Heart J. 1982; 23 (6): 1007-1013.
90. Ohara K, Kasegawa T, Ando T, et al. [Surgical treatment of coronary artery disease associated with aortitis syndrome].
Kyobu Geka. 1986; 39 (6): 423-431.
91. Tada Y, Sato O, Ohshima A, et al. Surgical treatment of Takayasu arteritis. Heart Vessels Suppl. 1992; 7: 159-167.
92. Sasaki S, Kubota S, Kunihara T, et al. Surgical experience of the thoracic aortic aneurysm due to Takayasu’s arteritis. Int J Cardiol. 2000; 75 Suppl 1: S129-134.
93. Fukushima K. [Aneurysmal dilatation in Takayasu’s arteritis--especialy, the long-term results of surgical and non-surgical treatment (author’s transl)]. Nippon Kyobu Geka Gakkai Zasshi. 1977; 25 (12): 1622-1642.
94. Ando M, Okita Y, Tagusari O, et al. A surgically treated case of Takayasu’s arteritis complicated by aortic dissections localized in the ascending and abdominal aortae. J Vasc Surg.
2000; 31 (5): 1042-1045.
95. Seko Y, Yazaki Y, Uchimura H, et al. A case of Takayasu’s disease with ruptured carotid aneurysm. Jpn Heart J. 1986;
27 (4): 523-531.
96. Liang P, Hoffman GS. Advances in the medical and surgical treatment of Takayasu arteritis. Curr Opin Rheumatol. 2005;
17 (1): 16-24.
97. Parra JR, Perler BA. Takayasu’s disease. Semin Vasc Surg.
2003; 16 (3): 200-208.
98. Taguchi J, Yamada K, Miyamoto Y, et al. Bypass surgery for aortitis syndrome: aortocarotid bypass with saphenous vein graft. Surg Neurol. 1992; 37 (4): 300-306.
99. Miyata T, Sato O, Deguchi J, et al. Anastomotic aneurysms after surgical treatment of Takayasu’s arteritis: a 40-year experience. J Vasc Surg. 1998; 27 (3): 438-445.
100. Tyagi S, Verma PK, Gambhir DS, et al. Early and long-term results of subclavian angioplasty in aortoarteritis (Takayasu disease): comparison with atherosclerosis.
Cardiovasc Intervent Radiol. 1998; 21 (3): 219-224.
101. Bali HK, Bhargava M, Jain AK, et al. De novo stenting of descending thoracic aorta in Takayasu arteritis: intermediate-term follow-up results. J Invasive Cardiol. 2000; 12 (12):
612-617.
102. Tyagi S, Kaul UA, Arora R. Endovascular stenting for unsuccessful angioplasty of the aorta in aortoarteritis.
Cardiovasc Intervent Radiol. 1999; 22 (6): 452-456.
103. Sharma S, Bahl VK, Saxena A, et al. Stenosis in the aorta caused by non-specific aortitis: results of treatment by percutaneous stent placement. Clin Radiol. 1999; 54 (1):
46-50.
104. Pajari R, Hekali P, Harjola PT. Treatment of Takayasu’s arteritis: an analysis of 29 operated patients. Thorac Cardiovasc Surg. 1986; 34 (3): 176-181.
105. Wang ZG, Gu YQ, Zhang J, et al. [Challenges in management of cerebral ischemia due to Takayasu’s arteritis].
Zhonghua Wai Ke Za Zhi. 2006; 44 (1): 14-17.
106. Rhodes JM, Cherry KJ, Jr., Clark RC, et al. Aortic-origin reconstruction of the great vessels: risk factors of early and late complications. J Vasc Surg. 2000; 31 (2): 260-269.
107. Cohen JR, Birnbaum E. Coarctation of the abdominal aorta.
J Vasc Surg. 1988; 8 (2): 160-164.
108. Taketani T, Miyata T, Morota T, et al. Surgical treatment of atypical aortic coarctation complicating Takayasu’s arteritis--experience with 33 cases over 44 years. J Vasc Surg. 2005;
41 (4): 597-601.
109. Kumar A, Dubey D, Bansal P, et al. Surgical and radiological management of renovascular hypertension in a developing country. J Urol. 2003; 170 (3): 727-730.
110. Weaver FA, Kumar SR, Yellin AE, et al. Renal revascularization in Takayasu arteritis-induced renal artery stenosis. J Vasc Surg. 2004; 39 (4): 749-757.
111. von Winiwarter F. Uber eine eigenthumliche Form von Endarteritis und Endophlebitis mit Gangran des Fusses. Arch Klin Chir. 1879; 23: 202-226.
112. 田中苗太郎．特発脱疽について．日外会誌．1903; 5:
120-143.
113. 三島好雄．Buerger病．現代外科学大系〈年間追補〉，中
山書店，東京．1978; 1978-D: 261-277.
114. Gulati SM, Madhra K, Thusoo TK, et al. Autoantibodies in thromboangiitis obliterans (Buerger’s disease). Angiology.
1982; 33 (10): 642-651.
115. Adar R, Papa MZ, Halpern Z, et al. Cellular sensitivity to collagen in thromboangiitis obliterans. N Engl J Med. 1983;
308 (19): 1113-1116.
116. Roncon de Albuquerque R, Delgado L, Correia P, et al.
Circulating immune complexes in Buerger’s disease.
Endarteritis obliterans in young men. J Cardiovasc Surg (Torino). 1989; 30 (5): 821-825.
117. Majewski W, Marszalek A, Staniszewiski R, et al. Clinical and morphological aspects of Buerger’s disease. Int Angiol.
1997; 16 (4): 239-244.
118. Eichhorn J, Sima D, Lindschau C, et al. Antiendothelial cell antibodies in thromboangiitis obliterans. Am J Med Sci. 1998;
315 (1): 17-23.
119. Olin JW. Thromboangiitis obliterans (Buerger’s disease). N Engl J Med. 2000; 343 (12): 864-869.
120. Ohta T, Ishioashi H, Hosaka M, et al. Clinical and social consequences of Buerger disease. J Vasc Surg. 2004; 39 (1):
176-180.
121. Ohta T, Shionoya S. Fate of the ischaemic limb in Buerger’s disease. Br J Surg. 1988; 75 (3): 259-262.
122. Olin JW, Young JR, Graor RA, et al. The changing clinical spectrum of thromboangiitis obliterans (Buerger’s disease).
Circulation. 1990; 82 (5 Suppl): IV3-8.
123. Matsushita M, Nishikimi N, Sakurai T, et al. Decrease in prevalence of Buerger’s disease in Japan. Surgery. 1998; 124 (3): 498-502.
124. Haga E. Über spontane Gangren. Arch Path Anat. 1898;
152: 26-60.
125. Allen E, Brown G. Thrimboangiitis obliterans. A clinical study of 200 cases. Ann Intern Med. 1928; 1: 535-549.
126. Iwai T, Inoue Y, Umeda M, et al. Oral bacteria in the occluded arteries of patients with Buerger disease. J Vasc
Surg. 2005; 42 (1): 107-115.
127. Yamamoto K, Iwase S, Mano T, et al. Muscle sympathetic outflow in Buerger’s disease. J Auton Nerv Syst. 1993; 44 (1): 67-75.
128. Roncon de Albuquerque R, Serrao P, Vale-Pereira R, et al.
Plasma catecholamines in Buerger’s disease: effects of cigarette smoking and surgical sympathectomy. Eur J Vasc Endovasc Surg. 2002; 24 (4): 338-343.
129. B o z k u r t A K , K o k s a l C , E r c a n M . T h e a l t e r e d hemorheologic parameters in thromboangiitis obliterans: a new insight. Clin Appl Thromb Hemost. 2004; 10 (1): 45-50.
130. McLoughlin GA, Helsby CR, Evans CC, et al. Association of HLA-A9 and HLA-B5 with Buerger’s disease. Br Med J.
1976; 2 (6045): 1165-1166.
131. Smolen JS, Youngchaiyud U, Weidinger P, et al.
Autoimmunological aspects of thromboangiitis obliterans (Buerger’s disease). Clin Immunol Immunopathol. 1978; 11 (2): 168-177.
132. de Moerloose P, Jeannet M, Mirimanoff P, et al. Evidence for an HLA-linked resistance gene in Buerger’s disease.
Tissue Antigens. 1979; 14 (2): 169-173.
133. Aerbajinai W, Tsuchiya T, Kimura A, et al. HLA class II DNA typing in Buerger’s disease. Int J Cardiol. 1996; 54 Suppl: S197-202.
134. Chen Z, Takahashi M, Naruse T, et al. Synergistic contribution of CD14 and HLA loci in the susceptibility to Buerger disease. Hum Genet. 2007; 122 (3-4): 367-372.
135. Saito S, Ota S, Yamada E, et al. Allele frequencies and haplotypic associations defined by allelic DNA typing at HLA class I and class II loci in the Japanese population. Tissue Antigens. 2000; 56 (6): 522-529.
136. Avcu F, Akar E, Demirkilic U, et al. The role of prothrombotic mutations in patients with Buerger’s disease.
Thromb Res. 2000; 100 (3): 143-147.
137. Hada M, Sakihama T, Kamiya K, et al. Cellular and humoral immune responses to vascular components in thromboangiitis obliterans. Angiology. 1993; 44 (7): 533-540.
138. Makita S, Nakamura M, Murakami H, et al. Impaired endothelium-dependent vasorelaxation in peripheral vasculature of patients with thromboangiitis obliterans (Buerger’s disease). Circulation. 1996; 94 (9 Suppl): II 211-215.
139. Halacheva K, Gulubova MV, Manolova I, et al. Expression of ICAM-1, VCAM-1, E-selectin and TNF-alpha on the endothelium of femoral and iliac arteries in thromboangiitis obliterans. Acta Histochem. 2002; 104 (2): 177-184.
140. Pietraszek MH, Choudhury NA, Baba S, et al. Serotonin as a factor involved in pathophysiology of thromboangiitis obliterans. Int Angiol. 1993; 12 (1): 9-12.
141. Halacheva KS, Manolova IM, Petkov DP, et al. Study of anti-neutrophil cytoplasmic antibodies in patients with thromboangiitis obliterans (Buerger’s disease). Scand J Immunol. 1998; 48 (5): 544-550.
142. Kurozumi T, Tanaka K. Buerger’s Disease: Histology and
Pathogenesis. Vasc Endovascular Surg. 1978; 12: 63-68.
143. 由谷親夫．ビュルガー病．血管炎アトラス（尾崎承一，
吉木敬 編）．2005: 43-45.
144. Hirai M, Shinonoya S. Intermittent claudication in the foot and Buerger’s disease. Br J Surg. 1978; 65 (3): 210-213.
145. Shionoya S. Clinical manifestation in Buerger’s disease.
The University of Nagoya press. 1990: 101-117.
146. Kobayashi M, Nishikimi N, Komori K. Current pathological and clinical aspects of Buerger’s disease in Japan. Ann Vasc Surg. 2006; 20 (1): 148-156.
147. Sasaki S, Sakuma M, Kunihara T, et al. Distribution of arterial involvement in thromboangiitis obliterans (Buerger’s disease): results of a study conducted by the Intractable Vasculitis Syndromes Research Group in Japan. Surg Today.
2000; 30 (7): 600-605.
148. Kroger K, Kreuzfelder E, Moser C, et al. Thrombangitis obliterans: leucocyte subpopulations and circulating immune complexes. Vasa. 2001; 30 (3): 189-194.
149. Brodmann M, Renner W, Stark G, et al. Vascular endothelial growth factor expression in patients suffering from thrombangitis obliterans. Int J Cardiol. 2001; 80 (2-3):
185-186.
150. 太田敬，保坂実，石橋宏之, et al．客観的な重症度評価
からみた間歇性跛行肢の治療法選択基準．脈管学．2002;
42: 171-179.
151. Komiyama T, Shigematsu H, Yasuhara H, et al. An objective assessment of intermittent claudication by near-infrared spectroscopy. Eur J Vasc Surg. 1994; 8 (3): 294-296.
152. 市木正隆，大内博．近赤外線分光法を臨床応用した間歇
性跛行肢の重症度評価法．脈管学．1995; 25: 53-59.
153. Shionoya S. Buerger’s disease. Pathology, Diagnosis and Treatment. The University of Nagoya press. 1990: 118-150.
154. 阪口周吉，三島好雄．血管造影所見報告 ｡: Buerger病に
ついて． 年度厚生省特定疾患系統的血管病変に関す る調査研究班分科会報告書．1977: 1-38.
155. 阪口周吉，馬場正三，亀田正，他．膠原病における末梢
循環障害─その動脈造影所見について─1976 年度厚生省 特定疾患系統的血管病変に関する調査研究班分科会報告 書． 年度厚生省特定疾患系統的血管病変に関する調 査研究班分科会報告書．1977: 295-302.
156. 三島好雄，小林宏，大橋重信，他．膠原病に伴う四肢主
幹動脈障害─その動脈造影所見について─1976 年度厚生 省特定疾患系統的血管病変に関する調査研究班分科会報告 書． 年度厚生省特定疾患系統的血管病変に関する調 査研究班分科会報告書．1977: 295-302.
157. 大城孟，劉懋忠，高橋顕，他．膠原病性末梢循環障害患
者の血管造影所見．脈管学．1979; 19: 87-92.
158. 太田敬，加藤量平，数井秀器，他．上肢動脈閉塞症の臨
床的検討．脈管学．1990; 30: 453-456.
159. Shionoya S. What is Buerger’s disease? World J Surg. Jul 1983; 7 (4): 544-551.
160. 中島伸之．バージャー病．難治性血管炎の診療マニュア
ル.厚生科学研究特定疾患対策研究事業．難治性血管炎に 関する調査研究班．2002: 9-12.
161. 重松邦弘，重松宏，安田慶秀．Buerger病の長期予後に
ついて．難治性血管炎に関する調査研究.平成 年度総括・
分担研究報告書．2004: 115-119.
162. 阪口周吉，田辺達三，三島好雄，他．慢性動脈閉塞症に
対するberaprost sodium（PGI2 誘導体）の薬効評価．臨床 と研究．1990; 67: 575-582.
163. 三島好雄，田辺達三，阪口周吉，他．慢性動脈閉塞症に
対するOPC-13013 の薬効評価─チクロピジンを対象薬と
す る 二 重 盲 検 比 較 試 験 ─．医 学 の あ ゆ み．1986; 193:
133-157.
164. 古川欽一，田辺達三，星野俊一，他．慢性動脈閉塞症に
対する塩酸サルポクレラート (MCI-9042)の治療成績─塩 酸 チ ク ロ ピ ジ ン と の 二 重 盲 検 比 較 試 験 ─．臨 床 医 薬．
1991; 7: 1747-1770.
165. Sakaguchi S, Kusaba A, Mishima Y, et al. A multi-clinical double blind study with PGE, (alpha-cyclodextrin clathrate) in patients with ischemic ulcer of the extremities. VASA.
1978; 7 (3): 263-266.
166. 勝村達喜，上道哲，大城孟，他．慢性動脈閉塞症に対す
るLipo PGE1 の臨床的有用性の検討．循環器科．1986; 20:
331-350.
167. 重松宏監訳．下肢閉塞動脈硬化症の診断，治療指針Ⅱ．
下肢閉塞動脈硬化症の診断，治療指針Ⅱ．日本語版，日本 脈管学会編．2007: 44-45.
168. 稲葉雅史．Buerger病─最近の動向─バージャー病に対
する治療法の選択「バイパス術」．血管外科．2003; 22:
35-37.
169. 太田敬．Buerger病─最近の動向─Over View．血管外科．
2003; 22: 15-19.
170. 正木久男，稲田洋，村上泰治，他．下肢慢性動脈閉塞症
のbelow Knee bypassの 遠 隔 成 績．日血外会誌．1996; 5:
1-8.
171. 岩塚靖，櫻井恒久，山本清人，他. バージャー病に対す
る硬膜外刺激電極法．厚生省特定疾患難治性血管炎調査研 究班 年度研究報告書．1991: 67-69.
172. Shigematsu H, Shigematsu K. Factors affecting the long-term outcome of Buerger’s disease (thromboangiitis obliterans). Int Angiol. 1999; 18 (1): 58-64.
173. Tateishi-Yuyama E, Matsubara H, Murohara T, et al.
Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet. 2002; 360 (9331):
427-435.
174. 森下竜一．特集─慢性閉塞性動脈硬化に対する血管新生
療法の新展開─遺伝子治療，HGF. Angiology Fontier. 2006;
5: 11-18.
175. 松原弘明，本庄尚謙，五十殿弘二，他．特集─慢性閉塞
性動脈硬化に対する血管新生療法の新展開─細胞治療,自 家骨髄単核球による血管再生治療─TACT臨床研究─．
Angiology Fontier. 2006; 5: 35-39.
176. 森谷純治，館野馨，南野徹，他．特集─慢性閉塞性動脈
硬化に対する血管新生療法の新展開─細胞治療，末梢血単 核球．Angiology Fontier. 2006; 5: 41-46.
177. 重松宏．虚血肢に対するHGFプラスミドを用いた血管